S&P 500
$5,823.76
-0.3%
-$18.25
DJI
$41,752.11
-0.3%
-$106.98
NASDAQ
$18,822.39
-0.5%
-$103.34
Bitcoin
109,510.00
-1.9%
-2,164.23
AAPL
$195.87
-2.7%
-$5.49
AMZN
$202.20
-0.4%
-$0.90
GOOG
$171.04
-0.5%
-$0.94
META
$631.86
-0.7%
-$4.71
MSFT
$453.53
-0.3%
-$1.33
NVDA
$131.97
-0.6%
-$0.86
TSLA
$342.17
+0.3%
+$1.13
Pharvaris (NASDAQ: PHVS)
$16.04
(-2.1%)
-$0.35
Price as of May 23, 2025, 1:18 p.m. ET
Pharvaris Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pharvaris Company Info
Pharvaris NV operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. Its PHA121 program is designed to treat all sub-types of hereditary angioedema. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.